Compare Gilead Sciences, Inc. (GILD) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SpaceX — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 10.5× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| GILD | SPCX | |
|---|---|---|
Market Cap | $168.35B | $1.76T |
Sector | Health | Technology |
52-Week High | $155.80 | $202.09 |
52-Week Low | $110.56 | $108.27 |
Enterprise Value | $191.42B | $1.70T |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
SPCX stock trades at $146.22, up 5.39% today, buoyed by strong technical momentum and positive news flow. The stock shows bullish moving average signals and trades above key support levels. Recent Q2 earnings beat expectations, though the company remains unprofitable with a net income margin of -35.66%. High-profile institutional investments, including Norway's sovereign wealth fund, underscore growing confidence in SpaceX's AI and Starlink growth trajectory.
Outlook is optimistic given analyst consensus and AI-driven revenue potential, but risks include persistent losses, high valuation multiples, and insider share unlocks. The consensus price target of $228.52 implies significant upside if execution aligns with ambitious growth plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
